Document:

Exhibit 10.8

 

	
  

  	
   

  	
  Photogen Technologies, Inc

  140 Union Square Drive

  New Hope, PA 18938

  Phone  (215) 862-6860

  Fax  (215) 862-7139

  

 

October
28, 2002

 

Taffy J. Williams, Ph.D.

103 Colwyn Terrace

Lansdale, PA 19446

 

Dear Dr. Williams:

 

At the close of the financing
(expected to occur at the end of October 2002), you agree that the terms of
your employment with Photogen Technologies, Inc. will be as specified in this
letter and that any previous conditions of employment are no longer effective.

 

Title and
Reporting Relationship

 

Your title and reporting
will remain unchanged: President and Chief Executive Officer reporting directly
to the Board of Directors.  You will be
expected to work full time for Photogen, reside in the Philadelphia/Princeton
region and work out of the New Hope, Pennsylvania office.

 

Salary and
Benefits

 

Promptly following the
closing, you will be paid the amount of your salary that had been deferred
since February 1, 2002 as well as any contractual bonus.

 

Your new annual salary will
be $275,000 (less applicable withholding and deductions). Payments will be made
on a semi-monthly basis in accordance with Company policy. Bonuses, if any,
will be at the sole discretion of the Board of Directors. Your expenses for
Company approved travel will be paid, subject to proper documentation.

 

The Company will provide you
with the following benefits:

 

•              Vacation of four weeks
annually of which only one week can be carried into the following year

 

•              Nine Company holidays plus
two discretionary “floating” days

 

•              Company paid
medical and dental coverage for you and eligible dependents

 

•              Salary deferral under our
401(k) Plan (currently, the Company does not make any contribution to the
401(k) Plan)

 

•              Other benefits
at the discretion of the Company

 

Stock Options

 

You agree to waive the
accelerated vesting provisions of any existing stock option awards that you may
have that would arise as a result of a change of control pursuant to either the
Corporate Separation or Institutional Financing transactions that are described
in the Company’s proxy statement and supplemental proxy statement for its 2002
Annual Meeting of Shareholders.

 

You will be awarded new
stock options to purchase 7.5% of the fully diluted shares of Photogen
Technologies, Inc.’s common stock (less any existing option with an exercise
price of $2.75 or less) at an exercise

 

 

Taffy J. Williams, Ph.D.

October 29, 2002

 

price equal to the offering price for the
financing syndicate, approximately $0.27 on a pre-split basis; the price and
absolute number of shares are subject to the 1 for 4 reverse split that will
take place post close of the financing. The vesting of the new award will be
30% immediate vesting (although you must agree not to sell or trade the newly
granted options for one year following the closing of the financing) with the
remainder vesting on a four-year ratable schedule. These options will be
subject to an Option Award Agreement that you will be required to sign.

 

Severance

 

Your employment is at-will
and can be terminated by you or Photogen at any time with or without cause. If
the Company terminates you for any reason other than for cause, the Company
will pay you severance equal to one year of your then-current salary (less
applicable withholding and deductions). All severance payments will be paid on
a semi-monthly basis in accordance with the Company’s regular payroll schedule.
If you terminate your employment or are terminated for cause, the Company will
not make any severance payments. “Cause” means:

 

•                             Material breach
of this Agreement where such breach, if curable, is not remedied to the
Company’s reasonable satisfaction within thirty (30) days after written notice
to you (and termination shall be effective as of the end of such 30-day
period); or

 

•                             Committing an
act of fraud, embezzlement, theft or another act involving moral turpitude (and
termination shall be effective upon written notice to you) that materially and
adversely affects the company.

 

As a condition of your
employment, you agree to be bound to the previously signed Employee
Confidentiality, Inventions and Noncompetition Agreement and amendments
required for closure of the financing. If not already provided, you must also
provide proof of citizenship or of your ability to be employed in the United
States.

 

Please signify your
acceptance of these terms by signing and dating this letter. We look forward to
your continuation with the Photogen team.

 

	
   

  	
  Sincerely,

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Robert J. Weinstein

  	
   

  
	
   

  	
  Robert J. Weinstein, M.D.

  
	
   

  	
  Director

  
	
   

  	
   

  
	
   

  	
   

  
	
  ACCEPTED BY:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/ Taffy J. Williams

  	
   

  	
   

  
	
  Taffy J. Williams, Ph.D.

  	
   

  
	
   

  	
   

  
	
  Dated:

  	
  10/29/02

  	
   

  	
   

  
						

 

2Exhibit 10.9

 

	
  

  	
   

  	
  Photogen Technologies, Inc

  140 Union Square Drive

  New Hope, PA 18938

  Phone (215) 862-6860

  Fax (215) 862-7139

  

 

October 28, 2002

 

Mr. Brooks Boveroux

2 Abey Drive

Pennington, N.J. 08534

 

Dear Mr. Boveroux:

 

At the close of the
financing (expected to occur at the end of October 2002), you agree that the
terms of your employment with Photogen Technologies, Inc. will be as specified
in this letter and that any previous conditions of employment are no longer
effective.

 

Title and
Reporting Relationship

 

Your title and reporting
will remain unchanged: Senior Vice President of Finance and Chief Financial
Officer reporting directly to the President and Chief Executive Officer.  You will be expected to work full time for
Photogen, reside in the Philadelphia/Princeton region and work out of the New
Hope, Pennsylvania office.

 

Salary and
Benefits

 

Promptly following the
closing, you will be paid the amount of your salary that had been deferred
since February 1, 2002 as well as any contractual bonus.

 

Your new annual salary will
be $225,000 (less applicable withholding and deductions). Payments will be made
on a semi-monthly basis in accordance with Company policy.  Bonuses, if any, will be at the sole
discretion of the Board of Directors. Your expenses for Company approved travel
will be paid, subject to proper documentation.

 

The Company will provide you
with the following benefits:

 

•              Vacation of four weeks
annually of which only one week can be carried into the following year

 

•              Nine Company
holidays plus two discretionary “floating” days

 

•              Company paid
medical and dental coverage for you and eligible dependents

 

•              Salary deferral under our
401(k) Plan (currently, the Company does not make any contribution to the
401(k) Plan)

 

•              Other benefits
at the discretion of the Company

 

Stock
Options

 

You agree to waive the
accelerated vesting provisions of any existing stock option awards that you may
have that would arise as a result of a change of control pursuant to either the
Corporate Separation or Institutional Financing transactions that are described
in the Company’s proxy statement and supplemental proxy statement for its 2002
Annual Meeting of Shareholders.

 

You will be awarded new
stock options to purchase 3% of the fully diluted shares of Photogen Technologies,
Inc.’s common stock (less any existing option with an exercise price of $2.75
or less) at an exercise

 

 

Brooks Boveroux

October 29, 2002

 

price equal to the offering price for the
financing syndicate, approximately $0.27 on a pre-split basis; the price and
absolute number of shares are subject to the 1 for 4 reverse split that will
take place post close of the financing. 
The vesting of the new award will be 30% immediate vesting (although you
must agree not to sell or trade the newly granted options for one year
following the closing of the financing) with the remainder vesting on a
four-year ratable schedule.  These
options will be subject to an Option Award Agreement that you will be required
to sign.

 

Severance

 

Your employment is at-will and
can be terminated by you or Photogen at any time with or without cause. If the
Company terminates you for any reason other than for cause, the Company will
pay you severance equal to 6 months of your then-current salary (less
applicable withholding and deductions). 
All severance payments will be paid on a semi-monthly basis in
accordance with the Company’s regular payroll schedule. If you terminate your
employment or are terminated for cause, the Company will not make any severance
payments. “Cause” means:

 

•                             Material breach
of this Agreement where such breach, if curable, is not remedied to the
Company’s reasonable satisfaction within thirty (30) days after written notice
to you (and termination shall be effective as of the end of such 30-day
period); or

 

•                             Committing an
act of fraud, embezzlement, theft or another act involving moral turpitude (and
termination shall be effective upon written notice to you) that materially and
adversely affects the company.

 

As a condition of your
employment, you agree to be bound to the previously signed Employee
Confidentiality, Inventions and Noncompetition Agreement and amendments
required for closure of the financing. If not already provided, you must also
provide proof of citizenship or of your ability to be employed in the United
States.

 

Please signify your
acceptance of these terms by signing and dating this letter. We look forward to
your continuation with the Photogen team.

 

	
   

  	
  Sincerely,

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Taffy Williams

  	
   

  
	
   

  	
  Taffy Williams, Ph.D.

  
	
   

  	
  President and Chief Executive
  Officer

  
	
   

  	
   

  
	
   

  	
   

  
	
  ACCEPTED BY:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/ Brooks Boveroux

  	
   

  	
   

  
	
  Brooks Boveroux

  	
   

  
	
   

  	
   

  
	
  Dated:

  	
  Oct. 28, 2002

  	
   

  	
   

  
					

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]